The relevant disclosure is attached.

Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel 0124 492 1033 Fax 0124 492 1041 Emergency 105010 Email: secretarial@fortishealthcare.com Website : www.fortishealthcare.com August 06, 2026 FHL/SEC/2026-27 The National Stock Exchange of India Ltd. BSE Limited Scrip Symbol: FORTIS Scrip Code: 532843 Sub: Press Release under Regulation 30 SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Dear Madam/Sir, Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed herewith the ‘Press Release’ for the quarter ended June 30, 2026. The date and time of occurrence of event is Thursday, August 06, 2026 at 6:45 PM (IST). This is for your information and records. Thanking you, Yours Sincerely, For Fortis Healthcare Limited Satyendra Chauhan Company Secretary & Compliance Officer M. No. - A14783 Encl : As stated above FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel :0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 Press Release August 06, 2026 Fortis Healthcare announces Q1 FY27 Financial Results ➢ Consolidated Revenues at INR 2,545 Cr, up 17.5%; Operating EBITDA Margin at 22.3% (vs Q1 FY26 at 22.6%) ➢ Hospital Business Revenues at INR 2,187 Cr, up 19.0%; Operating EBITDA margin at 21.5% (vs Q1 FY26 at 22.1%) Gurugram, August 06, 2026: Fortis Healthcare Ltd. (“Fortis” or the “Company”), amongst India’s leading healthcare delivery companies, today announced its unaudited consolidated financial results for the quarter ended June 30, 2026. Q1 Financial Highlights % Change % Change Consolidated (INR Cr) Q1 FY26 Q1 FY27 Q4FY26 Y-o-Y Q-o-Q Revenue 2,167 2,545 17.5% 2,365 7.6% Operating EBITDA# 491 568^ 15.8% 531 6.9% Operating EBITDA Margin 22.6% 22.3%^ 22.5% Profit Before Tax 338 354 4.6% 337 5.0% (Before exceptional items) Exceptional items 13 10 -13 Profit After Tax* 267 273 2.3% 271 0.6% Profit After Tax after Minority 260 266 2.3% 266 0.2% Interest and Share in Associates* # Operating EBITDA excludes Other Income ^ Q1 FY27 Operating EBITDA and margin excludes ESOP expenses of ~INR 31 Cr. Including the ESOP expenses the operating margin stood at 21.1%. * Q1 FY27 and Q1 FY26 PAT and PATMI includes exceptional gain of INR 9.5 Cr and INR 12.6 Cr respectively, which pertains primarily to reversal of impairment in an associate Company. * Q4 FY26 PAT and PATMI includes exceptional loss of INR 12.5 Cr which primarily pertains to impairment in an associate Company. % Change % Change Hospital Business (INR Cr) Q1 FY26 Q1 FY27 Q4FY26 Y-o-Y Q-o-Q Revenue 1,838 2,187 19.0% 2,023 8.1% Operating EBITDA 406 471* 15.9% 446 5.4% Operating EBITDA Margin 22.1% 21.5%* 22.1% * Q1FY27 Operating EBITDA and margin excludes ESOP expenses of ~INR 30 Cr. Including the ESOP expenses the Operating EBITDA margin stood at 20.1%. % Change % Change Diagnostics Business (INR Cr) Q1 FY26 Q1 FY27 Q4FY26 Y-o-Y Q-o-Q Revenue^ 369 407 10.2% 387 5.0% Operating EBITDA 85 97* 14.9% 85 14.4% Operating EBITDA Margin 23.0% 23.9%* 22.0% ^ Diagnostics business revenue is on Gross Basis; Consolidated financials include diagnostics business revenue net of intercompany elimination; Net Revenues stood at INR 358 Cr in Q1FY27 versus INR 329 Cr in Q1FY26. *Q1FY27 Operating EBITDA and margin excludes ESOP expenses of INR 0.7 Cr. Including the ESOP expenses the Operating EBITDA margin stood at 23.8% Press Release August 06, 2026 Balance Sheet • The Company’s net debt as of 30th June 2026 stood at INR 2,233 Cr with a Net Debt to EBITDA of 1.01x as compared to 0.92x as on 30th June 2025 (basis Q1 annualized EBITDA). Net debt to equity was at 0.21x versus 0.20x as on 30th June 2025. HOSPITAL BUSINESS HIGHLIGHTS KPIs Q1 FY26 Q1 FY27 Q4 FY26 Occupancy 69% 69% 68% ARPOB (INR Cr p.a.) 2.64 2.71 2.56 ALOS (Days) 4.09 4.19 4.26 • Revenue growth in the hospital business for the quarter was led by a moderate increase in ARPOB and an increase of 16.7% in occupied beds compared to Q1 FY26. The performance for the quarter also included recent acquisitions primarily related to the new hospital acquisitions in Punjab and Bengaluru and the leased facility in Delhi NCR. Excluding the impact of these facilities, on a like for like basis Operating EBITDA margins in the quarter were similar to Q1 FY 26 at 22%. • The Company entered into an Operations and Management agreement for a 300- bedded greenfield multi-specialty hospital to be constructed in Cuttack, marking Fortis Healthcare's entry into Odisha. The Company endeavors to work on similar arrangement lines including those related to operations and management contracts, healthcare services agreements and direct lease arrangements. The focus would be to capitalize on opportunities in dense catchment areas in its key clusters such as Delhi NCR that will augment further the Company’s already well-established presence in the select micro-markets. • As a part of the Company’s inorganic growth strategy, the Company aims to build on its portfolio of facilities in key focus clusters and evaluate opportunities to further consolidate its shareholding in group businesses. Geographies such as Bengaluru and other key clusters comprise select micro markets where the Company is pursuing inorganic growth forays to further bolster its presence. In due course, these would enable it to draw network synergy advantages and attain a market leadership position in such select micro-markets. • Along with an impetus on inorganic growth, the Company’s ongoing brownfield expansion plans would also witness an addition of ~1,800 capacity beds over the next 4 to 5 years, making it well-positioned to meet the increasing demand for advanced healthcare in India. Over such time period, the consolidated business (including both hospital and diagnostics) is expected to achieve revenue growth in line with the market growth. On an expanded bed base and given the potential for higher operating leverage coupled with a robust medical program mix, Operating EBITDA margins are expected to gradually improve to mid-twenties in the next few years. Press Release August 06, 2026 DIAGNOSTICS BUSINESS HIGHLIGHTS • Continuing with its network expansion strategy, primarily the addition of new customer touch points (CTPs); total CTPs as on 30th June 2026 stood at 4,493. • In Q1 FY27, Agilus conducted ~10.46 Mn tests versus ~10.13 Mn tests in Q1 FY26. • The preventive and specialized portfolio revenues in Agilus’ overall revenues grew 27% and 13% respectively in Q1 FY27 compared to corresponding previous period. Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “Building on the momentum of the previous year, we have made a positive start to the financial year, delivering a steady Q1 performance across both our hospital and diagnostics businesses. We recently entered into an O&M agreement for a 300-bedded greenfield multi-specialty hospital to be developed in Cuttack. This marks Fortis Healthcare's entry into Odisha, further expanding our presence in growth markets. Our recent acquisitions in our focus geographies are ramping up well. We also continued to invest in our medical infrastructure by expanding our robotic systems across key facilities, reinforcing our commitment to clinical excellence and technology led care.” He further added “The diagnostics business also witnessed a steady revenue growth along with an improvement in EBITDA margins compared to the corresponding period of the previous year. We remain focused on delivering sustained growth across both our businesses over the remaining quarters of the financial year, supported by our expansion plans, strategic growth initiatives and a continued focus on operational excellence.” About Fortis Healthcare Limited: Fortis Healthcare Limited is a leading integrated healthcare d [Showing first 8,000 characters — download PDF for full document]